[Clinical experiences in the prevention of alveolitis after administration of Apernyl, Pharodoran and Traumacel D].
D000700:Analgesics / Q000627:therapeutic use*; D000933:Antifibrinolytic Agents / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use*; D004338:Drug Combinations / Q000627:therapeutic use; D004368:Dry Socket / Q000517:prevention & control*; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D062385:Hydroxybenzoates / Q000627:therapeutic use*; D010226:Parabens / Q000627:therapeutic use*; D014574:Uronic Acids / Q000627:therapeutic use*
D000700:Analgesics; D000933:Antifibrinolytic Agents; D004338:Drug Combinations; D006490:Hemostatics; D062385:Hydroxybenzoates; D010226:Parabens; D014574:Uronic Acids; C018402:traumacel; C045763:pharodoran; C006608:aspirin, 4-hydroxybenzoic acid propyl ester, drug combination; D001241:Aspirin
Klinické zkusenosti s prevencí alveolitid po aplikaci apernylu, pharodoranu a traumacelu d.